• Tanuja Bisht
• Meenakshi Kandwal
• Shivanand Patil

The research delves into the innovative application of nanotechnology in the realm of drug delivery, specifically focusing on the efficacy of nanostructures in administering Elobixibat to enhance treatment outcomes for irritable bowel syndrome (IBS). The study begins with an extensive review of existing literature, meticulously identifying gaps and areas ripe for innovation. Building upon these insights, the research employs advanced characterization and analytical techniques, including Ultraviolet-visible (UV) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and various forms of microscopy, to meticulously design, develop, and evaluate Elobixibat-loaded nanoformulations. Preliminary results reveal a marked improvement in drug delivery efficiency, showcasing the potential of these nanoformulations in achieving enhanced bioavailability, targeted delivery, and sustained release profiles. This could translate into more effective management of IBS symptoms, reducing the frequency and severity of episodes. The study not only highlights the promising outcomes in preclinical models but also lays the groundwork for future research. It suggests a roadmap for clinical trials aimed at validating the safety and efficacy of these novel formulations in human subjects. Further optimization of the nanoformulations is proposed, focusing on enhancing their performance, minimizing potential side effects, and ensuring consistent therapeutic outcomes. The research underscores the importance of targeted delivery strategies that could offer enhanced specificity, reducing off-target effects and improving patient adherence to the treatment regimen. A patient-centric approach is advocated, emphasizing personalized treatment options that cater to individual patient needs and variability in disease presentation. The study also addresses the critical aspects of regulatory approval and cost-effectiveness, which are pivotal for the widespread adoption and equitable access to nanoformulation-based therapies. By navigating these challenges, the research aims to make significant contributions to the field of IBS treatment, potentially offering improved patient outcomes and a better quality of life. This thesis represents a substantial advancement in therapeutic strategies for IBS, highlighting the transformative potential of nanotechnology in modern medicine. It opens new avenues for research and development, paving the way for innovative, effective, and patient-friendly treatment options that could revolutionize the management of chronic gastrointestinal

Nanoparticles, Drug Release, FTIR, Permeation, Retention, Solubility

"Nanotechnology in Gastrointestinal Therapeutics: Optimizing Elobixibat Delivery for Irritable Bowel Syndrome Management", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 9, page no.f590-f616, September-2024, Available :http://www.jetir.org/papers/JETIR2409596.pdf

"Nanotechnology in Gastrointestinal Therapeutics: Optimizing Elobixibat Delivery for Irritable Bowel Syndrome Management", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 9, page no. ppf590-f616, September-2024, Available at : http://www.jetir.org/papers/JETIR2409596.pdf